Oncogenic YAP accelerates S-phase entry by shortening G1, leading to replication stress and sensitivity to CHK1 inhibition.

Kymera’s programme focuses on removing CDK2 from cells compared to other therapies that target the protein’s inhibition.

During therapy, some cancer cells evolve to escape elimination. Newer anticancer drugs that can overcome this resistance are ...

A new study from Weill Cornell Medicine-Qatar (WCM-Q), a member of Qatar Foundation, is drawing global attention for its ...

Metformin use may enhance progression-free survival (PFS) in patients receiving first-line systemic therapy for patients with ...

A compound best known for giving almonds and apricots their aroma may be the key to defeating hard-to-kill cancer cells. Japanese researchers found that benzaldehyde can stop the shape-shifting ...

BMPER attenuated PI3K/AKT signaling and suppressed BMP4-driven smooth muscle activation in models of PAH. BMPER overexpression mitigated the vascular remodeling that characterizes pulmonary arterial ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...